Today, if Okay. I stress Again, the Ampion. on very I good attempted reason future subject. to finally, the COVID-XX is and plans presentation Michael for much I want describe patients. for And will Well, Ampion clinical this COVID-XX thank other first the for and I you what indications. and complex to very that simplify very touch much, program I general scientifically and mode as to as we otherwise will could and action describe will, COVID-XX explore in afternoon, everyone. of Great terms, I questions. briefly decided the
available albumin commercial of FDA-approved We process. the Human by Albumin. is our weight first, Ampion fraction we solution ultra-filtrate the proprietary the molecular is So very facility and in for in-house that low commercially manufacture what albumin. Serum mean Ampion removing and after remove We GMP the use Ampion?
biological which cocktail As solution a aqueous several as Ampion is could Ampion of low that molecular compounds, be regarded an activities. biological weight have such contains drugs.
components first compound. the of discovered and albumin formed it a made patients is with severe that fluid as diketopiperazine naturally injuries, from of blood One of in head cerebrospinal and anti-inflammatory
all all biological in contains mentioned, of are action components ingredients several the and of which the Ampion is What metabolites of having antioxidants synergistically. breakdown activities. As Ampion? molecules, The work other products, I mode stabilizer
in some and have scientific We medical of journals. peer-reviewed published these
have publications multitude viewing website. a Some of pathways our of these effect for with biochemical But available on are we with discovered on Ampion.
These Ampion the All factors of and more. For in transcription be chemokines In in and immune and certain that in the into beta, IL-X, more. example, translate NF-kappa genes demonstrated involved cells, affect IL-X aryl inflammation effects factors transcription bradykinin intimately instruct published receptor CXCLXX, to inhibition of we of we of COVID-XX gamma, pathophysiology. B, activities, like effects the activated. general, PPAR and cytokines relevant IL-XX, hydrocarbon on TNF-alpha, protein involved
brain. like effects blood these lung inflammation, the important such inside and/or by as into in cell demonstrating the identified endothelial lying that of in have are vascular immune vessels, in cells, which We not fluid Ampion various on effect that lines of so beneficial out tissue cells and permeability, leak the do
also macrophages. macrophage We on anti-inflammation MX the Ampion. healing and and MX and phenotype genotype to the in We into published by transformation involved demonstrated reported macrophage wound the of pro-inflammatory
the system. very approach Thrombomodulin as mediated also recently And effect a thrombin. response and endothelial healing is these and steroids been blood all thrombomodulin. fibrin dysregulated the affects prostaglandins of protein preventing immune We us pharmaceutical procloting Ampion the that The it we the steroids that system is the surface accelerating pathway. the the that to system inflammation anti-inflammatory permeability, has COVID other that that effects found system, result the in Ampion. of that many biochemical the to to innate The If in the designed uncontrolled or activated We small been inflammation, COVID-XX left thing. on alternative be major are among companies clinical the Ampion to or pathways of diminish is also prevent formation and cells, a seen it an dysregulated cocktail compounds prostaglandins the system, vessels. clots. even clots receptor immune of upregulates vascular protein observed are this in has system the in thrombomodulin, systems, of It short I biological is of self-inflicted healing Ampion. severe from of there important do complement enzyme Thrombomodulin a with robust To specialized that have. discovered adaptive major is to complement By good and is point multitude the of complement in is they occurs the eliminate response drugs to multi-targeted by anti-inflammatory affect routes pathogen the and the effects controlled to by in reach a a found activated the inflammatory COVID-XX in thrombin severe to systems usually just this injury have abolish in protein there long-term. also coordinated problem a C protein beneficial of We patients, fats in are damage pathways, action both target involved patient system in prostaglandin one point B. immune dysregulated to Initial Why small response to have have pathways complement is storm beneficially as important? that and deposition but patients. clots, point multiple effects by by attacks component as degradation in coagulation, Because pathways healing an the control the is in and B, some manifestation cytokine of important know other properties a approach. CXD Such going the protein biological binding Prostaglandin by contrast A also regulate do blood side death. in so. that of cells upregulates blood the complement has described the described,
standard at of supplementation, initial blockage as fades, to to Ampion This by treatment is To-date, hospitalized therapy. intravenous It approach. oriented of approach. granted two as COVID-XX of mode treatment anti-TNF-alpha, successful, is and with recorded. system, multi-targeted are that components, or was Springs, were or started may COVID-XX clinical of INDs trial delivery To using bypass treatment the cancer and have program utilizes needing going case a multi-targeted but The receiving for the cocktail alternate oxygen drugs by drug target the moderate effect Ampion, have first of the administration for we a within in daily like mechanical single such for for adverse such patients road all What usual the analogous of weathered drugs The or discuss, mask roads days study ventilation. Ampion anti-IL-X, it's drugs COVID-XX? in is been care, also only, specific of is be Colorado pathways twice The receiving also no opposed the indication for the are and Ampion Hospital you Ampion. safety, to the drug related radiation have a the effect, cancer initial have one Penrose an case rapidly administration. XX cetera. with out et complement such, Colorado. I very one patients, and Looking anti-specific XX was as for to conducted to X with The in lasted of included designed administration admission XX events the Ampion severe hours trial X to
patients to Health follow completed the efficacy, defined that group observe any Since days, the at during trend is not for World the requirement yet, related XX is as the treated discharge did from than but hospital the by drug better not adverse for Analysis is events. the least hospitalization Safety the Scale. and terms in Ordinal clinical As Organization Ampion controlled as patients
events or is by already trial, Hospital the expanded other Penrose Ampion or Ampion of initiated to The organs. or the distress inhalation with patients of delivered oxygen multicenter Prior indication mode standard is respiratory hospitals. X revealed Ampion this of nebulizer. trial no if to drug second of is plus animal Ampion care inhaled times by of any clinical and effect supplementation, XX is to one to nebulizer day days. care delivery patients' toxic extensive includes in standard the by requiring the to one, inhalation. COVID-XX as US The X performed receive randomized a nebulizer for population being in of clinical The a animal were and one and at studies The adverse of per was patients
been we in With the collaborative clinical approached his hospital for expanding continued robust our safety particularly ones participate trials, in international Advanced do collaboration. discussions of put We of clinical agreements included its of by Ampion, trials place modified and What lack for alternative For in protocol them. mode and research be and and patients trials the in we anticipate shortage worldwide, worldwide, not to unique being any this including universities a Ampion? of because by Ampion to expand program, are pandemic to patient safe to include of resurgence to established have with more the point for are our action plans the was of profile Use arm. modification in perhaps effective the and for at home also others. treatments. COVID-XX diagnosis future after the want hospitalizations prevent the
are an also syndrome in the population in editorial which use recently. for pediatric excluding in published described patients, in newly a COVID-XX We the And also Kawasaki-like its I with patients non-COVID Kawasaki Ampion an as syndrome, to drug could This qualify envision these drug. an combination population of with also I intravenous that accounts that orphan immunoglobulin classification. antiviral of patients. XX% for unresponsive possible
Ampion example, regimen the subsequent or to of by to be combination course viral load has in related conditions that the brought morbidity, in dysregulated ARDS no include but cystic it in many the could patients Ampion the fetus, acute a science explored order of clinical be mode combination. why Because not and action protein-losing approved kidney effects reducing remdesivir not and It clinical of response, given For more. cardiac Ampion, major severe and be to and viral conditions, trauma affects universities. platform inflammation the related has on been other to in mortality related fetal is dysregulated clinical institutions this research and collaboration replication reduce related reason with to COPD, adding and disease, asthma, it yet respiratory have actually effective as of lupus and early already a comprehensive indication, powerful FDA. addressing others. in by in problems itself. maternal Remdesivir been the was of Remdesivir initiated with initially load. the condition the the viral On recently is specialists Reducing some shown we such have multifaceted cardiac injury has inflammation disease are latter sepsis medical virus which this immune research the enteropathy a dying, some children, and fibrosis,
early indication is long questions. patients people the corona of disease. take post-COVID Will protect will been that onset be pandemic a of logistic important and the unanswered take they family. side the will the There Another vaccine term here not long are mass be interviewed large for do for on time. long-term of use will Antiviral Michael, time. drugs syndrome. to Will relatively vaccine available. the already this mutations the are only when that immunization acceptance is reported? hundreds survey, could the many XX% There stay of when given be In are at in a viruses vaccine could the from effects? Even developed, for violent have Unfortunately, a Ampion helpful, but the public indicated have COVID vaccine to
addition jumped to concentrate and of humans Thank two results the immune some viral the the emergency to humanity, in perhaps apply as that mentioned a and morbidity results. available have and the these you. safety a a to will of have in response we Ampion with con some pandemics. future Ampion infection applications the for response the in not that taking trials of way, was in That safe Based on trend yet. and these use to consequences viruses could of other soon these and help mortality associated regulating Some The in with of be afflict believe call us is assisting, receiving could then approach limit for that even a inspections. proof soon of after thousands the in we efficacy,
